Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble

The 3C-like protease (3CL(pro)) of SARS-CoV-2 is a potential therapeutic target for COVID-19. Importantly, it has an abundance of structural information solved as a complex with various drug candidate compounds. Collecting these crystal structures (83 Protein Data Bank (PDB) entries) together with those of the highly homologous 3CL(pro) of SARS-CoV (101 PDB entries), we constructed the crystal structure ensemble of 3CL(pro) to analyze the dynamic regulation of its catalytic function. The structural dynamics of the 3CL(pro) dimer observed in the ensemble were characterized by the motions of four separate loops (the C-loop, E-loop, H-loop, and Linker) and the C-terminal domain III on the rigid core of the chymotrypsin fold. Among the four moving loops, the C-loop (also known as the oxyanion binding loop) causes the order (active)-disorder (collapsed) transition, which is regulated cooperatively by five hydrogen bonds made with the surrounding residues. The C-loop, E-loop, and Linker constitute the major ligand binding sites, which consist of a limited variety of binding residues including the substrate binding subsites. Ligand binding causes a ligand size dependent conformational change to the E-loop and Linker, which further stabilize the C-loop via the hydrogen bond between the C-loop and E-loop. The T285A mutation from SARSCoV 3CL(pro) to SARS-CoV-2 3CL(pro) significantly closes the interface of the domain III dimer and allosterically stabilizes the active conformation of the C-loop via hydrogen bonds with Ser1 and Gly2; thus, SARS-CoV-2 3CL(pro) seems to have increased activity relative to that of SARS-CoV 3CL(pro).(C) 2021 The Author(s). Published by Elsevier Ltd.

Automated summary

This study highlights the potential therapeutic target of SARS-CoV-2 3CL(pro) for COVID-19 and analyzes its dynamic regulation. By examining the crystal structure ensemble, the motion characteristics of loops like C-loop and ligand binding sites were identified, as well as the impact of the T285A mutation on conformation.